Real‐world experiences with direct‐acting antiviral agents for chronic hepatitis C treatment

• Published in: Journal of viral hepatitis Vol. 27; no. 2; pp. 195 - 204
• Main Authors: Daniel, Kimberly E., Saeian, Kia, Rizvi, Syed
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.02.2020
• Subjects: Adult; Aged; Aged, 80 and over; Antiviral agents; Antiviral Agents - therapeutic use; Ascites; Cirrhosis; Clinical trials; Demography; direct‐acting antivirals; Drug Therapy, Combination; Female; Genotype; Genotypes; Hemodialysis; Hepacivirus - drug effects; Hepacivirus - genetics; Hepatitis; Hepatitis C; Hepatitis C, Chronic - drug therapy; HIV; Human immunodeficiency virus; Humans; Interferon; Kidney transplantation; Liver Cirrhosis; Liver transplantation; Male; Middle Aged; Patients; Retrospective Studies; Sustained Virologic Response; Treatment Outcome; Veterans; Veterans Health - statistics & numerical data; Young Adult; veterans; sustained virologic response; hepatitis C; direct-acting antivirals
• ISSN: 1352-0504; 1365-2893
• DOI: 10.1111/jvh.13218

As direct‐acting antiviral (DAA) agents become more readily available for the treatment of chronic hepatitis C, it is important to understand real‐world treatment experiences. In order to assess the effectiveness of DAA regimens and factors that influence sustained virologic response (SVR) rates in the Veterans Affairs healthcare system, we retrospectively identified veterans with chronic hepatitis C who were treated with DAAs from January 2014 to June 2015. We determined SVR rates and collected data on demographics, genotype (GT), previous interferon‐based treatment, antiviral regimens, and co‐morbidities (HIV, prior solid organ transplant, haemodialysis) for analysis. Of 15 720 veterans, the majority were infected with genotype 1a (GT1a, 60.5%). Excluding the special populations, the overall cohort SVR rate was 92%. Compared to treatment‐experienced patients, treatment‐naïve patients had significantly higher SVR rates (90% vs 92%, P = .006). Subgroups associated with lower likelihood of achieving SVR‐included African Americans (OR 0.79, 95% CI 0.69‐0.91), GT3 (OR 0.65, CI 0.50‐0.86), and cirrhosis (OR 0.91, CI 0.84‐0.99) or decompensated cirrhosis (ascites: OR 0.78, CI 0.67‐0.91, variceal bleed: OR 0.75, CI 0.57‐0.99). The only treatment regimen independently associated with lower SVR rates was SOF+RBV+IFN (OR 0.65, CI 0.50‐0.84). Special populations achieved high SVR rates: HIV 92%, haemodialysis 93%, liver transplant 96% and renal transplant 94%. In conclusion, overall SVR rates were comparable to those reported in clinical trials and carried over to historically more difficult‐to‐treat patients. Several patient‐ and treatment‐related factors were identified as independent predictors of treatment failure and suggest subgroups to target for efforts to improve therapeutic strategies.